Table 7 Registered CAR-NK clinical trials
From: Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Origin | NCT number | Target | Extra feature | Source of NK cells | Indication | Trial Phase (Ph) | Trial status | Sponsor and country |
|---|---|---|---|---|---|---|---|---|
Industry | GDCT0392921 | EGFR | Daratumumab | FcRγ-deficient NK (PB-derived) | Glioblastoma | Ph 0 | Planned | Indapta Therapeutics, USA |
GDCT0392823 | NKG2D | None | Allogeneic, off-the-shelve | AML/MDS/liver cancer | Ph 0 | Planned | NKarta, USA | |
Not available | EGFR | None | iPSC-derived NK | Glioblastoma | Ph 0 | Planned | Cytova Therapeutics, USA | |
NCT04050709 | Her2 | PD-L1 | NK-92 cell line | Locally Advanced Solid Tumor | Ph I | Ongoing, recruiting | NantKwest Inc, USA | |
NCT04052061 | CD19 | None | NK-92 cell line | B Cell Lymphoma | Ph I | Ongoing | NantKwest Inc, USA | |
NCT03692663 | PSMA | Cyclophosphamide | NK-92 cell line | Prostate Cancer | Ph I | Ongoing | NantKwest Inc, USA | |
Not available | CD19/CD22 | unknown | PB-NK | B-ALL | Ph I | Planned | Avalon GloboCare Corp, China | |
Not available | CD19/CD22 | unknown | PB-NK | Non-Hodgkin Lymphoma | Ph I | Planned | Avalon GloboCare Corp, China | |
Not available | EpCAM | unknown | NK101 cell line | Ovarian Cancer | Ph I | Planned | SL Bigen Inc, South Korea | |
Not available | IL13Rα | unknown | NK101 cell line | Glioblastoma | Ph I | Planned | SL Bigen Inc, South Korea | |
Not available | FLT3 | unknown | NK101 cell line | AML | Ph I | Planned | SL Bigen Inc, South Korea | |
Not available | BCMA (GoCAR-NK) | IL-15 | Primary NK cells | Multiple Myeloma | Preclinical | Planned | Bellicum Phamaceuticals | |
NCT02944162 | CD33 | None | NK-92 cell line | AML | Ph I | Ongoing, recruiting | PersonGen Biomedicine Suzhou Co Ltd, China | |
NCT03941457 | ROBO1 (BiCAR) | None | NK-92 cell line | Metastatic Pancreatic Cancer | Ph I/II | Ongoing, recruiting | Asclepius Technology Company Group Suzhou Co Ltd, China | |
NCT03940833 | BCMA | None | NK-92 cell line | Multiple Myeloma | Ph I/II | Ongoing, recruiting | Asclepius Technology Company Group Suzhou Co Ltd, China | |
NCT03940820 | ROBO1 | None | NK/T | Malignant Neoplasms | Ph I/II | Ongoing, recruiting | Asclepius Technology Company Group Suzhou Co Ltd, China | |
NCT02892695 | CD19 | None | NK-92 cell line | Leukemia | Ph I/II | Planned | PersonGen Biomedicine Suzhou Co Ltd, China | |
NCT02742727 | CD7 | None | NK-92 cell line | AML, T-cell leukemia, lymphoma | Ph I/II | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd, China | |
NCT02839954 | MUC1 | None | NK-92 cell line | HCC, NSCLC, pancreatic carcinoma, TN breast cancer, glioma, CRC, gastric carcinoma | Ph I/II | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd, China | |
NCT04639739 | CD19 | None | NK cell | relapsed and refractory B cell non-Hodgkin lymphoma | Ph 0 | Planned | Xinqiao Hospital, Chongqing, China | |
Academic | NCT03056339 | CD19 | chemotherapy + BSCT | CB-NK | B cell lymphoma or leukemia | Ph I/II | Ongoing | M.D. Anderson Cancer Center, USA |
NCT03383978 | HER2 | None | NK-92 cell line | Glioblastoma | Ph I/II | Ongoing | Johann W. Goethe University Hospital, Germany | |
NCT01974479 | CD19 | IL-2 sc | PB-NK on K562-mbIL15-41BBL | ALL | Ph I/II | Suspended for an interim review | National University Health System, Singapore |